Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PXVX0047 for adenovirus infection
NCT03160339Phase 1Terminated
- Sponsor
- Emergent BioSolutions
- Start
- May 2017
- Primary completion
- Nov 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PXVX0047 in adenovirus infection (2 arms), sponsored by Emergent BioSolutions. Primary endpoints: Incidence and severity of solicited adverse events, Incidence and severity of unsolicited adverse events and 2 more. Started May 2017; status: terminated.
02
Drugs
PXVX0047
03
Conditions
adenovirus infection
Beyond the preview
Go deeper on NCT03160339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03160339.